REVIEW

Myocarditis after COVID-19 mRNA vaccination: A systematic review of case reports and case series

Dae Yong Park MD1 | Seokyung An BS2 | Amandeep Kaur MD3 | Saurabh Malhotra MD, MPH4,5 | Aviral Vij MD4,5

1Department of Medicine, John H. Stroger Jr Hospital of Cook County, Chicago, Illinois, USA
2Department of Biomedical Science, Seoul National University Graduate School, Seoul, Korea
3Department of Pathology, McGaw Medical Center at Northwestern University, Chicago, Illinois, USA
4Division of Cardiology, Cook County Health, Chicago, Illinois, USA
5Division of Cardiology, Rush Medical College, Chicago, Illinois, USA

Correspondence
Aviral Vij, MD, John H. Stroger Jr Hospital of Cook County, 1901 W. Harrison St, Suite 3620, Chicago, IL 60612, USA.
Email: aviral.vij@cookcountyhhs.org

Abstract

Background: The coronavirus disease of 2019 (COVID-19) is a global pandemic with over 266 million cases and 5 million deaths worldwide. Anti-COVID-19 vaccinations have had exceptional success in subduing the incidence, prevalence, and disease severity of COVID-19, but rare cases of myocarditis have been reported after COVID-19 vaccinations.

Hypothesis: Myocarditis occurring after COVID-19 mRNA vaccinations have distinguishable clinical characteristics. They usually have a favorable prognosis.

Methods: We performed a systematic literature search on PUBMED and MEDLINE database from inception to December 5, 2021. Studies were analyzed based on predetermined eligibility criteria.

Results: A total of 57 studies containing 275 cases of COVID-19 vaccine-associated myocarditis were catalogued. Mean age was 26.7 years and male to female ratio was 14:1. For 86.9% of patients, myocarditis occurred after the second dose. Average time to onset and length of hospitalization were 3.7 and 3.9 days, respectively. Prognosis was largely benign, but there was a 1.1% reported mortality. Chest pain (95.2%), elevation of troponin (100%), and ST elevation on electrocardiography (68.5%) were common. Nonsteroidal anti-inflammatory drugs (81.4%) were the most used medication, followed by colchicine (33.1%).

Conclusions: Patients with COVID-19 vaccine-associated myocarditis are usually younger males presenting with chest pain 3–4 days after receiving their second dose of COVID vaccine. Diagnosis is made by exclusion of all other etiologies. Given significant population benefit from COVID-19 vaccination, physicians should continue to encourage vaccination while remaining vigilant of the very rare occurrence of myocarditis following COVID-19 vaccination.

Abbreviations: BNP, brain natriuretic peptide; CDC, Centers for Disease Control and Prevention; COVID-19, coronavirus disease of 2019; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LVEF, left ventricular ejection fracture; mRNA, messenger ribonucleic acid; NSAIDs, nonsteroidal anti-inflammatory drugs; WBC, white blood cell; VAERS, Vaccine Adverse Event Reporting System.

Dae Yong Park and Seokyung An contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
1 | INTRODUCTION

Large multinational efforts have been made to battle the highly contagious SARS-CoV-2 virus. Within a year after the COVID-19 pandemic began, multiple vaccines had been developed, mass produced, and commercialized. On December 11, 2020, the US Food and Drug Administration sanctioned the first emergency use authorization for Pfizer-BioNTech’s COVID-19 vaccine (BNT162b2), followed by Moderna’s COVID-19 Vaccine (mRNA-1273) on December 18, 2020, and Janssen’s COVID-19 Vaccine (Ad26.COV2.S) on February 27, 2021.1 Since their approval, the vaccines have been administered to millions of people around the world, playing a major role in decreasing the transmissibility and mortality from COVID-19 among the vaccinated.2

While the vaccines have a remarkable safety record, there have been some reports of adverse reactions, ranging from fever, fatigue, and headache to anaphylaxis, thrombosis with thrombocytopenia syndrome, and Guillain–Barre syndrome.3 In particular, myocarditis is being recognized as a rare complication of COVID-19 mRNA vaccinations, a finding also addressed by the Centers for Disease Control and Prevention (CDC).3 The CDC had reported a total of 296 million messenger ribonucleic acid (mRNA) COVID-19 vaccine doses administered by the June of 2021, when the Vaccine Adverse Event Reporting System (VAERS) indicated a total of 1226 reports of myocarditis after mRNA vaccination.4 At a similar time, the CDC reported the number of myocarditis cases observed within 7 days after the second dose of the vaccine was significantly higher than expected.5,6 Similarly, in May 2021, Vigibase, an international pharmacovigilance database, indicated the occurrence of 1251 vaccine-associated myocarditis, of which 214 (17.1%) were linked to COVID-19 vaccines.7 With expansion of COVID-19 vaccination indications to children and need for additional booster vaccinations in adults, we performed an updated systematic review of COVID-19 vaccine-associated myocarditis, delineating its demographics and clinical characteristics.

2 | METHODS

We conducted a systematic review of the literature on myocarditis occurring after COVID-19 vaccination using the following search engines: PUBMED and MEDLINE. The search string was as follows: (1) for the outcome of interest, the following keyword was used: “myocarditis” and (2) for exposure, the following keywords were considered: “COVID,” “COVID-19,” “COVID19,” “SARS-CoV-2,” “mRNA,” “vaccine,” and “vaccination.” Cases pertaining to non-mRNA vaccinations were excluded. We selected all studies in English published up to December 5, 2021, which were individually assessed for eligibility. Duplicative studies on the same population and non-case reports were excluded. All cases were recorded, studied, and characterized. The PRISMA flow diagram for this study is shown in Figure 1. Included studies are summarized in Table 1 and Table S1.

**FIGURE 1** Flow diagram illustrating the systematic review selection process
| Author                | Year | Country  | Cases | Age(s) | Male (%) | Vaccines                  | Dose | LOS | Outcome |
|-----------------------|------|----------|-------|--------|----------|----------------------------|------|-----|---------|
| Bautista et al.       | 2020 | Spain    | 1     | 39     | 100      | 1 BNT162b2                  | 2nd  | 6   | Recovered |
| Dickey et al.         | 2021 | USA      | 6     | 16–40  | 100      | 5 BNT162b2, 1 mRNA-1273    | 2nd  | -   | Recovered |
| Mansour et al.        | 2021 | USA      | 2     | 21–25  | 50       | 2 mRNA-1273                 | 2nd  | 3 (1), ¬(1) | Recovered |
| Neve et al.           | 2021 | Israel   | 3     | 20–24  | 100      | 3 BNT162b2                  | 2nd  | -   | Recovered |
| Habib et al.          | 2021 | Qatar    | 1     | 37     | 100%     | 1 BNT162b2                  | 2nd  | 6   | Recovered |
| Singh et al.          | 2021 | USA      | 1     | 24     | 100      | 1 BNT162b2                  | 2nd  | 4   | Recovered |
| Muthukumar et al.     | 2021 | USA      | 1     | 52     | 100      | 1 mRNA-1273                 | 2nd  | 4   | Recovered |
| Watkins et al.        | 2021 | USA      | 1     | 20     | 100      | 1 BNT162b2                  | 2nd  | -   | Recovered |
| D’Angelo et al.       | 2021 | Italy    | 1     | 30     | 100      | 1 BNT162b2                  | 2nd  | -   | Recovered |
| Abu Mouch et al.      | 2021 | Israel   | 6     | 16–45  | 100      | 6 BNT162b2                  | 2nd (5), 1st (1) | 6 | Recovered |
| Albert et al.         | 2021 | USA      | 1     | 24     | 100      | 1 mRNA-1273                 | 2nd  | -   | Recovered |
| Montgomery et al.     | 2021 | USA      | 23    | 20–51  | 100      | 7 BNT162b2, 16 mRNA-1273   | 2nd (20), 1st (3) | 7 (16), ¬(7) | Recovered |
| Rosner et al.         | 2021 | USA      | 6     | 19–39  | 100      | 5 BNT162b2, 1 mRNA-1273    | 2nd (5), 1st (1) | 3 | Recovered |
| McLean et al.         | 2021 | USA      | 1     | 16     | 100      | 1 BNT162b2                  | 2nd  | 6   | Recovered |
| Kim et al.            | 2021 | USA      | 4     | 23–70  | 75       | 2 BNT162b2, 2 mRNA-1273    | 2nd  | -   | Recovered |
| Shaw et al.           | 2021 | USA      | 4     | 16–31  | 50       | 3 BNT162b2, 1 mRNA-1273    | 2nd (2), 1st (2) | - | Recovered |
| Minocha et al.        | 2021 | USA      | 1     | 17     | 100      | 1 BNT162b2                  | 2nd  | 6   | Recovered |
| Park et al.           | 2021 | USA      | 2     | 15–16  | 100      | 2 BNT162b2                  | 2nd (1), 1st (1) | 4 | Recovered |
| Marshall et al.       | 2021 | USA      | 7     | 14–19  | 100      | 7 BNT162b2                  | 2nd  | 3.7 | Recovered |
| Kim et al.            | 2021 | Korea    | 1     | 29     | 100      | 1 BNT162b2                  | 2nd  | 1   | Recovered |
| Gautam et al.         | 2021 | USA      | 1     | 66     | 100      | 1 BNT162b2                  | 2nd  | -   | Recovered |
| Nguyen et al.         | 2021 | Germany  | 1     | 20     | 100      | 1 mRNA-1273                 | 1st  | -   | Recovered |
| Schmitt et al.        | 2021 | France   | 1     | 19     | 100      | 1 BNT162b2                  | 2nd  | 1   | Recovered |
| Patrignani et al.     | 2021 | Italy    | 1     | 56     | 100      | 1 BNT162b2                  | 1st  | -   | Recovered |
| Williams et al.       | 2021 | Canada   | 1     | 34     | 100      | 1 mRNA-1273                 | 2nd  | 5   | Recovered |
| Miqdad et al.         | 2021 | Saudi Arabia | 1 | 18     | 100      | 1 BNT162b2                  | 2nd  | 3   | Recovered |
| Ambati et al.         | 2021 | USA      | 2     | 16–17  | 100      | 2 BNT162b2                  | 2nd  | 3   | Recovered |
| Dionne et al.         | 2021 | USA      | 15    | 12–18  | 93.3     | 15 BNT162b2                 | 2nd (14), 1st (1) | 2 | Recovered |
| Ehrlich et al.        | 2021 | Germany  | 1     | 40     | 100      | 1 BNT162b2                  | 1st  | 4   | Recovered |
| Kim et al.            | 2021 | Korea    | 1     | 24     | 100      | 1 BNT162b2                  | 2nd  | -   | Recovered |
| Chelala et al.        | 2021 | USA      | 5     | 16–19  | 100      | 4 BNT162b2, 1 mRNA-1273    | 2nd  | 4.4 | Recovered |
| Patel et al.          | 2021 | USA      | 5     | 19–37  | 100      | 4 BNT162b2, 1 mRNA-1273    | 2nd (4), 1st (1) | 1.8 | Recovered |
| Tailor et al.         | 2021 | USA      | 1     | 44     | 100      | 1 mRNA-1273                 | 2nd  | 5   | Recovered |
| Abbate et al.         | 2021 | USA      | 2     | 27–34  | 50       | 2 BNT162b2                  | 2nd (1), 1st (1) | 73 (1), ¬(1) | Death (1), Recovered (1) | (Continues) |
We obtained baseline demographics such as age, sex, vaccine type (mRNA-1273, BNT-162b2), vaccine dose (first and second), time to onset, length of stay, symptoms, and vital signs at presentation, initial laboratory and testing data, and treatment used in the case studies. Cases that did not report any symptoms were classified as "not reported," and cases that reported some symptoms were assumed to be negative for those that were not mentioned. Continuous variables were presented as mean with standard deviations, and categorical variables were expressed as numbers and percentages. We employed Wilcoxon rank-sum test to compare the clinical characteristics of myocarditis occurring after mRNA-1273 and BNT-162b2 vaccines. All statistical analyses were performed using SAS 9.4 software (SAS Institute).

### RESULTS

We identified 201 studies relevant to COVID-19 vaccination and myocarditis. Further review identified a total of 57 studies reporting cases, case series, and summated case series of COVID-19 vaccine-associated myocarditis.\(^8\) A total of 275 cases of COVID-19 vaccine-associated myocarditis were reported. All cases were inpatient encounters. In most cases, a diagnosis of myocarditis was reached after considering clinical presentation and testing data, implementing diagnosis of exclusion, and applying the 2018 Lake-Louise consensus criteria on imaging findings. A few larger studies utilized CDC's case

| Author         | Year | Country       | Cases | Age(s) | Male (%) | Vaccines                     | Dose\(^a\) | LOS\(^b\) | Outcome        |
|----------------|------|---------------|-------|--------|----------|------------------------------|------------|-----------|----------------|
| Larson et al.  | 2021 | USA, Italy    | 8     | 21–56  | 100      | 5 BNT162b2, 3 mRNA-1273      | 2nd (7), 1st (1) | -         | Recovered      |
| Verma et al.   | 2021 | USA           | 2     | 42–45  | 50       | 1 BNT162b2, 1 mRNA-1273      | 1st (1), 2nd (1) | 7 (1), – (1) | Death (1), Recovered (1) |
| Koizumi et al. | 2021 | Japan         | 2     | 22–27  | 100      | 2 mRNA-1273                  | 2nd        | 4 (1), – (1) | Recovered      |
| Witberg et al. | 2021 | USA           | 54    | -      | 94.4     | 54 BNT162b2                  | -          | 3         | Recovered      |
| Hudson et al.  | 2021 | USA           | 2     | 22–24  | 100      | 2 BNT162b2                   | 2nd        | 1.5       | Recovered      |
| Starekova et al.| 2021 | USA          | 5     | 17–38  | 80       | 3 BNT162b2, 2 mRNA-1273      | 2nd        | -         | Recovered      |
| Murakami et al.| 2021 | Japan         | 2     | 27–38  | 100      | 2 BNT162b2                   | 2nd (1), 1st (1) | 9         | Recovered      |
| Perez et al.   | 2021 | USA           | 7     | 22–71  | 85.7     | 3 BNT162b2, 4 mRNA-1273      | 2nd (6), 1st (1) | 2.6       | Recovered      |
| Isak et al.    | 2021 | Germany       | 1     | 15     | 100      | 1 BNT162b2                   | 2nd        | 7         | Recovered      |
| Kau et al.     | 2021 | USA           | 2     | 21–28  | 100      | 1 BNT162b2, 1 mRNA-1273      | 2nd        | 3         | Recovered      |
| Shiyovich et al.| 2021 | Israel        | 15    | 17–76  | 100      | -                            | 2nd (10), 1st (5) | -         | Recovered      |
| Levin et al.   | 2021 | USA           | 4     | 20–30  | 75       | 1 BNT162b2, 3 mRNA-1273      | 2nd        | 2.5       | Recovered      |
| Visclosky      | 2021 | USA           | 1     | 15     | 100      | 1 BNT162b2                   | 2nd        | -         | Recovered      |
| King et al.    | 2021 | USA           | 4     | 20–30  | 75       | 1 BNT162b2, 3 mRNA-1273      | 2nd        | 2.3 (3), –(1) | Recovered      |
| Onderko et al. | 2021 | USA           | 3     | 25–36  | 100      | 2 BNT162b2, 1 mRNA-1273      | 2nd        | -         | Recovered      |
| Choi et al.    | 2021 | South Korea   | 1     | 22     | 100      | 1 BNT162b2                   | 1st        | -         | Death          |
| Das et al.     | 2021 | USA           | 25    | 12–17  | 88       | 25 BNT162b2                  | 2nd (22), 1st (3) | 2.7       | Recovered      |
| Schauer et al. | 2021 | USA           | 13    | 12–17  | 92.3     | 13 BNT162b2                  | 2nd        | -         | Recovered      |
| Chamling et al.| 2021 | Germany       | 2     | 20–25  | 100%     | 2 BNT162b2                   | 2nd (1), 1st (1) | -         | Recovered      |
| Tano et al.    | 2021 | USA           | 8     | 15–17  | 100%     | 8 BNT162b2                   | 2nd (7), 1st (1) | -         | Recovered      |
| Matta et al.   | 2021 | USA           | 1     | 27     | 100      | 1 BNT162b2                   | 2nd        | 1         | Recovered      |
| Alania et al.  | 2021 | Spain         | 1     | 28     | 100      | 1 BNT162b2                   | 2nd        | 10        | Recovered      |
| Kaneta et al.  | 2021 | Japan         | 1     | 25     | 100      | 1 mRNA-1273                  | 2nd        | -         | Recovered      |

\(^a\)Number within the parenthesis signifies the number of patients within the study corresponding to the said description.

\(^b\)Average length of stay in days.
definition for myocarditis. Four studies contained histopathologic evidence for myocarditis.

The average age of the patients with myocarditis was 26.7 years, with the youngest patient at 12 years and the oldest at 71 years. Males comprised 93.5% of the patient population, and the male to female ratio was 14:1. More than half (76.0%) of the patients were hospitalized for an average of 3.9 days. Death occurred in 3 (1.1%) patients. Table 2.

Excluding the 25 patients whose symptoms were not reported, chest pain (95.2%) was the most common symptom at presentation, followed by fever (30.8%), myalgia (18.0%), and dyspnea (13.2%). Presence of other symptoms are shown in Table 3. The mean body temperature of the patients was 37.4°C; mean systolic blood pressure, 121.9 mmHg; mean diastolic blood pressure, 72.3 mmHg; mean pulse rate, 84.6 beats per minute; mean respiratory rate, 18.2 breaths per minute; and the mean oxygen saturation, 98.0% on room air (Table 2).

Troponin was elevated in all 170 patients where troponin level was reported. The mean troponin I, high-sensitivity troponin I, and troponin T levels were 9.1 ng/ml, 1737 pg/ml, and 301.9 ng/L, respectively. Mean WBC, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), brain natriuretic peptide (BNP), and pro-BNP values are summarized in Table 2. Most common electrocardiogram finding was ST elevation (57.8%), followed by normal sinus rhythm (15.3%) and T wave inversion (10.9%). Mean left ventricular ejection fraction was 54.2%.

Among the 118 patients whose information on treatment was available, most common treatment included nonsteroidal anti-inflammatory drugs (NSAIDs) (81.4%), followed by colchicine (33.1%), beta-blocker (16.9%), and steroids (15.3%). Nine patients (7.6%) recovered despite receiving no treatment (Table 4).

The clinical characteristics of myocarditis occurring after Pfizer’s BNT162b2 vaccine and after Moderna’s mRNA-1273 vaccine were compared. The average time to onset after the BNT162b2 vaccine was 3.7 ± 7.21 days while that after the mRNA-1273 vaccine was 3.5 ± 3.84 days (p = .14). The average time of hospital stay for BNT162b2 vaccine-associated myocarditis was 3.6 ± 6.04 days, while that for mRNA-1273-associated myocarditis was 4.9 ± 2.20 days (p < .01). Troponin I was significantly greater with mRNA-1273 than BNT162b2 (p = .045). WBC, CRP, ESR, and BNP were not statistically different between the two types of mRNA vaccines (Table 2).

### 4 | DISCUSSION

Vaccines against SARS-CoV2 have been developed at an expedited pace and is a testament to the decades of knowledge gained from vaccine development and advances in biomedical technology. Vaccines, and not just the ones against SARS-CoV2, are associated with rare adverse effects, one of them being myocarditis.

Myocarditis occurring after vaccination is not an unprecedented phenomenon as demonstrated by the association of smallpox vaccine with myocarditis. One retrospective study in Israel postulated the incidence of myocarditis as 1 every 26,000 males and 1 every 218,000 females after the second COVID vaccine, having a rate ratio of 2.35 compared with unvaccinated persons. Another study of VAERS from December 2020 to August 2021 reported the incidence rate of 5.98 cases of myocarditis per million COVID vaccine doses.

The molecular makeup of prior vector-based vaccines and the current mRNA-lipid nanoparticles-based vaccines (BNT162b2 and mRNA-1273) are different. In the past, immune-mediated mechanisms were implicated for myocarditis due to vaccines. Similarly, antibody-mediated hypersensitivity and delayed-type hypersensitivity may be responsible for myocarditis after mRNA vaccines and could explain the occurrence of myocarditis after predominantly (86.9%) second dose of COVID-19 vaccination in most patients. The second dose of vaccines was typically scheduled 21–28 days after the first dose, allowing sufficient time for delayed-type hypersensitivity to develop. Given the presence of prior exposure and the interval time, either the first dose of the vaccine or in some cases previous COVID-19 infection may have exposed an epitope, priming the immune system against an entity in the myocardium via molecular mimicry or cross-reaction.

An alternate mechanism by which mRNA vaccines can elicit immunological response is by directly binding to pattern recognition receptors intracellularly. For example, Toll-like receptors and retinoic acid-inducible gene-I are known to recognize RNA in endosomes and cytosol, respectively, leading to cascades that activate cytokines and translate pro-inflammatory agents. A recent
TABLE 3  Clinical presentation of patients with myocarditis following COVID-19 vaccination

| Characteristics                      | N (%) | Characteristics                      | N (%) |
|---------------------------------------|-------|---------------------------------------|-------|
| Symptoms (n = 250)                    |       | Laboratory and testing variables      |       |
| Fever                                 |       | Troponin (n = 170)                    |       |
| Yes                                   | 77 (30.8) | Elevated | 170 (100) |
| No                                    | 173 (69.2) | Not elevated | 0 (0) |
| Chest pain                            |       | cTnl, mean (SD), ng/ml                |       |
| Yes                                   | 238 (95.2) | Peak cTnl, mean (SD), ng/ml          | 11.3 (11.5) |
| No                                    | 12 (4.8) | hs-cTnl, mean (SD), ng/L             | 1737 (2516) |
| Myalgia                               |       | Peak hs-cTnl, mean (SD), ng/L        | 4759 (5557) |
| Yes                                   | 45 (18.0) | cTnT, mean (SD), ng/L                | 302 (436) |
| No                                    | 205 (82.0) | Peak cTnT, mean (SD), ng/L           | 681 (441) |
| Headache                              |       | WBC (n = 43)                          |       |
| Yes                                   | 30 (12.0) | Normal | 34 (79.1) |
| No                                    | 220 (88.0) | Abnormal | 9 (20.9) |
| Dyspnea                               |       | WBC count, mean (SD), /μl            |       |
| Yes                                   | 33 (13.2) | CRP (n = 147) | 36 (24.5) |
| No                                    | 217 (86.8) | Elevated | 111 (75.5) |
| Dizziness                             |       | Not elevated                          |       |
| Yes                                   | 2 (0.8) | CRP, mean (SD), mg/L                 | 39 (39) |
| No                                    | 248 (99.2) | ESR (n = 42) | 19 (12) |
| Malaise                               |       | BNP (n = 34)                          |       |
| Yes                                   | 11 (4.4) | Elevated | 8 (23.5) |
| No                                    | 239 (95.6) | Not elevated | 26 (76.5) |
| Vomiting                              |       | BNP, mean (SD), pg/ml                |       |
| Yes                                   | 12 (4.8) | Pro-BNP (n = 19)                     | 11 (57.9) |
| No                                    | 238 (95.2) | Elevated | 8 (42.1) |
| Diaphoresis                           |       | BNP, mean (SD), pg/ml                |       |
| Yes                                   | 7 (2.8) | Normal | 758 (1158) |
| No                                    | 243 (97.2) | ECG (n = 232) | 42 (18.1) |
| Vital signs, mean (SD)                |       | ST elevation                          | 159 (68.5) |
| Temperature, °C                       | 37.4 (0.53) | ST depression | 8 (3.4) |
| SBP, mmHg                             | 121.9 (12.22) | PR depression | 21 (9.1) |
| DBP, mmHg                             | 72.3 (6.71) | T wave inversion | 30 (12.9) |
| PR, beats per minute                  | 84.6 (12.46) | Others* | 14 (6.0) |
| RR, breaths per minute                | 18.2 (3.19) | LVEF (n = 167) | 28 (16.8) |
| SpO₂, %                               | 98.0 (1.88) | <50% |
Comparison of the clinical course of myocarditis occurring after Pfizer’s BNT162b2 vaccine and that after Moderna’s mRNA-1273 vaccine suggested longer length of hospital stay and greater troponin I level in the latter. Although definite conclusions cannot be made on the differences in the severity of myocarditis between the two mRNA-based vaccines, the finding is consistent with that of a Danish study, which noted a significantly increased risk of myocarditis or myopericarditis after mRNA-1273 as opposed to a nonsignificantly increased risk after BNT162b2. The rate of myocarditis or myopericarditis was also more than threefold higher after mRNA-1273 compared to BNT162b2. These findings suggest that myocarditis occurring after mRNA-1273 may be more severe than that after BNT162b2, but the underlying mechanism remains elusive.

While the authors of the included case reports have hinted at a strong association between COVID-19 vaccines and myocarditis, a definite causal relationship cannot be established based on available data. Phase 3 trials of COVID-19 mRNA vaccines did not detect any major vaccine-associated myocarditis. While there might be apprehension among some patients and providers, the benefits of COVID-19 vaccination at preventing severe COVID-19 infections cannot be emphasized enough. Advisory Committee on Immunization Practices (ACIP) performed an individual-level assessment which concluded that the benefits of vaccination clearly outweighed the risks by preventing more than 11,000 COVID-19 cases, 560 hospitalizations, 138 intensive care unit admissions, and 6 deaths per million doses of vaccines compared to 39–47 expected myocarditis cases after vaccination in males aged 12–29 years. Vaccine recipients, providers, and healthcare workers should be aware of this very rare adverse effect of myocarditis after COVID-19 vaccination, but this should not be a reason to deter vaccination.

There are many unanswered questions. The true incidence of myocarditis after COVID-19 vaccinations is still unclear as association does not equal causation. Additionally, larger scale studies with longer follow ups are needed to assess long-term risks of cardiomyopathies or arrhythmias in those with vaccine-associated myocarditis? Duration of follow-up, safety of subsequent mRNA vaccine booster doses need to be addressed. Perhaps closer monitoring for 1 month should be practiced in patients with a history of COVID-vaccine-related myocarditis given that more than 99% of the cases occurred within 30 days from vaccination.

### TABLE 3 (Continued)

| Characteristics | N (%) | Characteristics | N (%) |
|-----------------|-------|-----------------|-------|
| ≥50% | 139 (83.2) | LVEF, mean (SD), % | 54.2 (9.6) |

Abbreviations: BNP, brain natriuretic peptide; CRP, C-reactive protein; cTnT, cardiac troponin T; DBP, diastolic blood pressure; ECG, electrocardiogram; ESR, erythrocyte sedimentation rate; hs-cTnI, highly sensitive cardiac troponin I; LVEF, left ventricular ejection fraction; PR, pulse rate; RR, respiratory rate; SBP, systolic blood pressure; SpO2, pulse oximeter oxygen saturation; WBC, white blood cell.

*Ectopic atrial rhythm, sinus tachycardia, nonsustained ventricular tachycardia, left axis deviation, incomplete right bundle branch block, J-point elevation, widened QRS, peaked T waves, AV dissociation, sinus bradycardia.

### TABLE 4 Clinical course and treatment of patients with myocarditis following COVID-19 vaccination

| Treatment (n = 118) | N (%) |
|---------------------|-------|
| NSAID | 96 (81.4) |
| Colchicine | 39 (33.1) |
| Steroids | 18 (15.3) |
| Beta-blocker | 20 (16.9) |
| IVIG | 14 (11.9) |
| Aspirin | 13 (11.0) |
| ACEI/ARB | 14 (11.9) |
| Acetaminophen | 10 (8.5) |
| Diuretics | 4 (3.4) |
| Spironolactone | 4 (3.4) |
| Vasopressors | 3 (2.5) |
| Anakinra | 2 (1.7) |
| No treatment given | 9 (7.6) |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; IVIG, intravenous immunoglobulin; NSAID, nonsteroidal anti-inflammatory drug.

study performed endometrial biopsy in two patients, consistently revealing inflammatory infiltrate consisting of macrophages, T cells, eosinophils, and B cells. Another study on biopsy-proven lymphocytic myocarditis following mRNA COVID-19 vaccination reported myocytes necrosis, CD68-positive macrophages, and numerous CD3-positive T cells, further corroborating the hypothesis that post-vaccine myocarditis occurs via an immunologic response.

The mean age of the 275 patients with myocarditis post-COVID-19 vaccination was 26.7 years, 93.5% of them were male. This predisposition to younger population may be due to stronger immune responses or immune naivety in the young. Previous studies have reported myocarditis to occur at a greater frequency in males, with a male to female ratio around 1.5:1 to 1.7:1. This differences in gender were thought to be due to genetics, effects of testosterone on the heart, influence of the sex hormones on the immune system, and difference in immune responses.
This systematic review inherently has many limitations. The total number of cases is relatively small as myocarditis after vaccination is a rare adverse event, and it has been only about a year since vaccines have rolled out. There is a possibility of selection bias where milder forms of COVID-19 vaccine-associated myocarditis may not have been reported or identified due to milder and nonspecific symptoms. There is also the possibility of older individuals with myocarditis being diagnosed with ischemic heart diseases as they tend to have more cardiovascular risk factors. Only published data including inpatient cases were included in the study. Clinical evaluations varied, and some authors omitted subjective symptoms and many of the objective values. The clinical workup was especially heterogeneous. Nonstandardized parameters and omissions imposed a great challenge in comparing the cases.

5 | CONCLUSION

Myocarditis is an extremely rare adverse effect that has been reported after COVID-19 vaccination; however, it should be considered as a differential in young adults with chest pain, fever, and dyspnea 3–4 days after vaccination. While patients should be informed of this rare occurrence, they should continue to receive counselling and education regarding the significant individual and population level benefits of COVID-19 vaccination.

AUTHOR CONTRIBUTIONS

Dae Yong Park and Seokyung An: Conceptualization, data curation, formal analysis, investigation, methodology, software, visualization, writing original draft, review, and editing. Amandeep Kaur: Review and editing. Saurabh Malhotra: Supervision, validation, review and editing. Aviral Vij: Project administration, resources, supervision, validation, review and editing.

ACKNOWLEDGMENT

No grants, contracts, or other forms of financial support was received.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

Data included in this study are publicly available as published articles in the literature.

ORCID

Dae Yong Park http://orcid.org/0000-0002-1486-7452
Seokyung An http://orcid.org/0000-0002-1971-1094

REFERENCES

1. COVID-19 Vaccines. U.S. Food & Drug Administration, 2021.
2. Macchia A, Ferrante D, Angeleri P, et al. Evaluation of a COVID-19 vaccine campaign and SARS-CoV-2 infection and mortality among adults aged 60 years and older in a middle-income country. JAMA Network Open. 2021;4:e2130800.
3. Safety of COVID-19 Vaccines. Centers for Disease Control and Prevention, 2021.
4. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:977-982.
5. ACIP Presentation Slides: June 23–25, 2021 Meeting. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention.
6. Bozkurt B, Kamat I, Hotze PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471-484.
7. Kermeis M, Bihan K, Salem JE. COVID-19 vaccines and myocarditis. Arch Cardiovasc Dis. 2021;114:515-517.
8. Abbate A, Gavin J, Madanchi N, et al. Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol. 2021;340:119-121.
9. Abu Mouch S, Roguin A, Hellou E, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021;39:3790-3793.
10. Alania-Torres E, Morillas-Climent H, Garcia-Esclavà A, et al. Case Report: Probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy. Front Cardiovasc Med. 2021;8:759119.
11. Albert E, Aurigemma G, Saucedo J, Gerson DS. Myocarditis following COVID-19 vaccination. Radiol Case Rep. 2021;16:2142-2145.
12. Ambati S, Colon M, Mihic M, Sanchez J, Bakar A. Acute myocarditis following COVID-19 vaccine in teenagers. Case Rep Cardiol. 2021;2021:826755.
13. Bautista Garcia J, Pena Ortega P, Bonilla Fernandez JA, Cardenes Leon A, Ramirez Burgos L, Caballero Dorta E. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol. 2021;74:812-814.
14. Chamlion B, Vehof V, Drakos S, et al. Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol. 2021;110:1850-1854.
15. Chelala L, Jeudy J, Hossain R, Rosenthal G, Pietris N, White C. Cardiac MRI findings of myocarditis after COVID-19 mRNA vaccination in adolescents. AJR Am J Roentgenol. 2021;218:651-657.
16. Choi S, Lee S, Seo J-W, et al. Myocarditis-induced sudden death after BNT162b2 mRNA COVID-19 vaccination in Korea: case report focusing on histopathological findings. J Korean Med Sci. 2021;36:e286.
17. D’Angelo T, Cattafi A, Carerj ML, et al. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction? Can J Cardiol. 2021;37:1665-1667.
18. Das BB, Kohli U, Ramachandran P, et al. Myopericarditis after messenger RNA Coronavirus Disease 2019 vaccination in adolescents 12 to 18 years of age. J Pediatr. 2021;238:26-32 e1.
19. Dickey JB, Albert E, Badr M, et al. A series of patients with myocarditis following SARS-CoV-2 vaccination with mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging. 2021;14:1862-1863.
20. Dionne A, Sperotto F, Chamberlain S, et al. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol. 2021;6:1446-1450.
21. Ehrlich P, Klingel K, Ohlmann-Knafo S, et al. Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol. 2021;110:1855-1859.
22. Gautam N, Saluja P, Fudim M, Jambhekar K, Pandey T, Al’Aref S. A late presentation of COVID-19 vaccine-induced myocarditis. Cureus. 2021;13:e17890.
Disease Control and Prevention, U.S Department of Health & Human Services; 2021.

67. Kimmel SR. Vaccine adverse events: separating myth from reality. Am Fam Physician. 2002;66:2113-2120.

68. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol. 2004;43:1503-1510.

69. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140-2149.

70. Li M, Yuan J, Lv G, Brown J, Jiang X, Lu ZK. Myocarditis and pericarditis following COVID-19 vaccination: inequalities in age and vaccine types. J Pers Med. 2021;11:1106.

71. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines— a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261-279.

72. Stone CA, Jr., Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019;85:2694-2706.

73. Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases". Clin Immunol. 2021;224:108665.

74. Mason JW, O’Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269-275.

75. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetopathogenetic features at diagnosis. Eur Heart J. 2007;28:1326-1333.

76. Magnani JW, Danik HJ, Dec GW, Jr., DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J. 2006;151:463-470.

77. Fairweather D, Cooper LT Jr, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38:7-46.

78. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384:403-416.

79. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Park DY, An S, Kaur A, Malhotra S, Vij A. Myocarditis after COVID-19 mRNA vaccination: A systematic review of case reports and case series. Clin Cardiol. 2022;45:691-700. doi:10.1002/clc.23828